Table 3.
CKD stagewise distribution of antidiabetic drugs in subjects with diabetes
| Drugs, n (%) | CKD stage (n) |
Total (N = 1467) | |||
|---|---|---|---|---|---|
| 1 (17) | 2 (93) | 3 (1200) | 4 (157) | ||
| Overall | 13 (76.5) | 57 (61.3) | 802 (66.8) | 87 (55.4) | 959 (65.4) |
| Insulin | 5 (29.4) | 13 (14.0) | 331 (27.6) | 39 (24.8) | 388 (26.4) |
| Sulfonylureas | 5 (29.4) | 33 (35.5) | 337 (28.1) | 32 (20.4) | 407 (27.7) |
| Metformin | 9 (52.9) | 28 (30.1) | 314 (26.2) | 26 (16.6) | 377 (25.7) |
| DPP4 inhibitors | 2 (11.8) | 11 (11.8) | 118 (9.8) | 9 (5.7) | 140 (9.5) |
| Others | 0 (0) | 6 (6.8) | 38 (3.2) | 10 (6.4) | 54 (3.6) |
| Not taking any antidiabetic drug | 4 (23.5) | 36 (38.7) | 398 (33.2) | 70 (44.5) | 508 (34.6) |
CKD, chronic kidney disease; DPP4, dipeptidyl-peptidase 4.